Plant Name: Rubia cordifolia
Taxonomic Information:
Plant ID: NPO26542
Plant Latin Name: Rubia cordifolia
Taxonomy Genus: Rubia
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
339321
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Africa; Tanzania; India; Rwanda; China; Kenya; South KoreaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMMedicinal Functions:
Alterative; Anodyne; Antiphlogistic; Antitussive; Astringent; Diuretic; Emmenagogue; Expectorant; Febrifuge; Styptic; Tonic; Vulnerary
Geographical Distribution:
South Africa; Tanzania; India; Rwanda; China; Kenya; South Korea
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; PIK3CB; PIK3CA; NQO2; HSD17B10; IDO1; | |
| CDC25B; | |
| ACHE; | |
| FYN; | |
| CA2; CA14; CA6; CA12; CA9; | |
| NR1H4; | |
| ESR1; | |
| PTGS2; MAOB; ALDH2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.710E-12 | 5.900E-08 | CA12, CA14, CA2, CA6, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.605E-10 | 1.046E-05 | CA12, CA14, CA2, CA6, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.944E-08 | 1.849E-04 | CA12, CA2, CA6, CA9 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 9.432E-08 | 2.567E-04 | ALDH2, CYP1A2, IDO1, MAOB, NQO2 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 7.121E-07 | 1.107E-03 | ALDH2, CYP1A2, IDO1, MAOB, NQO2 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.031E-06 | 4.232E-03 | CA2, CA9, CYP1A2, ESR1, FYN, MAOB, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.746E-06 | 5.875E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 9.862E-06 | 7.846E-03 | CYP1A2, IDO1, MAOB, NR1H4, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.009E-05 | 7.846E-03 | CYP1A2, CYP3A4, IDO1, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.687E-12 | 5.999E-10 | CA12, CA2, CA6, CA9, CA14 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.008E-08 | 5.125E-06 | MAOB, ALDH2, CYP1A2, IDO1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 5.000E-06 | 2.133E-04 | ACHE, PIK3CA, FYN, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.668E-05 | 8.077E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 3.453E-05 | 8.077E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 4.785E-05 | 8.077E-04 | PIK3CA, FYN, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.679E-05 | 8.077E-04 | PIK3CA, PIK3CB, ESR1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.999E-05 | 8.077E-04 | MAOB, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.446E-05 | 8.077E-04 | CA2, NR1H4, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 9.654E-05 | 1.123E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.423E-04 | 1.444E-03 | PIK3CA, PIK3CB, CDC25B |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.853E-04 | 1.581E-03 | MAOB, ALDH2, CYP1A2, PTGS2, CYP3A4, HSD17B10, IDO1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.467E-04 | 1.444E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.376E-05 | 1.072E-03 | CYP1A2, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.697E-04 | 1.552E-03 | PIK3CA, FYN, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.003E-04 | 1.602E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.464E-04 | 1.829E-03 | PIK3CA, PIK3CB, ESR1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.718E-04 | 1.829E-03 | PIK3CA, FYN, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.589E-04 | 1.829E-03 | PIK3CA, FYN, PIK3CB |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.426E-04 | 2.081E-03 | PIK3CA, FYN, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 3.659E-04 | 2.081E-03 | PIK3CA, FYN, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.739E-04 | 2.081E-03 | PIK3CA, FYN, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 4.421E-04 | 2.263E-03 | PIK3CA, FYN, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 5.795E-04 | 2.853E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.197E-03 | 4.790E-03 | PIK3CA, PIK3CB, ESR1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.181E-03 | 4.790E-03 | PIK3CA, FYN, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.150E-03 | 4.790E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.563E-03 | 5.715E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00280 | Valine, leucine and isoleucine degradation | 1.150E-03 | 4.790E-03 | ALDH2, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.349E-03 | 5.079E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.619E-03 | 5.755E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.536E-03 | 8.705E-03 | PIK3CA, PTGS2, CDC25B |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 1.012E-03 | 4.625E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 7.601E-04 | 3.603E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.792E-03 | 6.035E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.099E-03 | 6.292E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.035E-03 | 6.292E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.912E-03 | 6.274E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00330 | Arginine and proline metabolism | 1.248E-03 | 4.840E-03 | MAOB, ALDH2 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.163E-03 | 6.292E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.638E-03 | 6.754E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.498E-03 | 6.754E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.163E-03 | 6.292E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.228E-03 | 6.338E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.099E-03 | 6.292E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.675E-03 | 5.796E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.892E-03 | 9.225E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 3.723E-03 | 8.991E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.638E-03 | 6.754E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00340 | Histidine metabolism | 2.858E-04 | 1.829E-03 | MAOB, ALDH2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 4.241E-03 | 9.870E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 4.330E-03 | 9.898E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.191E-04 | 2.235E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 3.005E-03 | 7.543E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.638E-03 | 6.754E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAOB; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAOB; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | MAOB; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | IDO1; ESR1; PIK3CA; ACHE; PTGS2; PIK3CB; NQO2; CDC25B; CA9; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOB; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| NA: NA | Motor symptoms | NA | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | MAOB; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
